Cannatrek ‘evolution’ key to merger, says LGP managing director by Adam Sheldon February 3, 2026February 5, 2026 Leadership changes at Cannatrek and a renewed focus on financial discipline were key to Little Green […]
Epsilon posts strongest December quarter following ASX reinstatement by Adam Sheldon January 28, 2026January 28, 2026
Epsilon Healthcare resumes trading on ASX after two-year suspension by Steve Jones December 19, 2025December 22, 2025
Epsilon working with ASX as two-year suspension deadline approaches by Adam Sheldon December 9, 2025December 10, 2025
ECS Botanics completes A$1.95m raise to boost product and export plans by Adam Sheldon November 13, 2025February 21, 2026
Little Green Pharma revenue climbs 10% to $10m in September quarter by Adam Sheldon October 30, 2025November 3, 2025
News in brief: ASX questions Neurotech over funding; participants sought for endometriosis trial in Sydney by Adam Sheldon October 29, 2025February 21, 2026
One way or another we’ll list, says Biortica CEO as Bod deadline looms by Steve Jones September 24, 2025September 24, 2025
‘You can’t be a shrinking violet in this game’: Spring Sciences Australia prepares for IPO to drive expansion by Steve Jones July 31, 2025July 31, 2025
Althea resumes trading on ASX as board narrowly avoids a second shareholder revolt by Steve Jones February 3, 2025February 3, 2025
